Cue Biopharma (NASDAQ:CUE) Price Target Lowered to $4.00 at Stifel Nicolaus

Cue Biopharma (NASDAQ:CUE) had its price target decreased by Stifel Nicolaus from $8.00 to $4.00 in a report released on Tuesday, Benzinga reports. Stifel Nicolaus currently has a buy rating on the stock.

Several other analysts have also recently commented on the stock. Piper Sandler reduced their target price on shares of Cue Biopharma from $8.00 to $3.00 and set an overweight rating for the company in a research note on Friday, July 26th. JMP Securities reduced their target price on shares of Cue Biopharma from $15.00 to $2.00 and set a market outperform rating for the company in a research note on Friday, July 26th. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, Cue Biopharma has a consensus rating of Buy and a consensus price target of $5.00.

Cue Biopharma Trading Down 5.6 %

Shares of Cue Biopharma stock opened at $0.77 on Tuesday. Cue Biopharma has a 1 year low of $0.58 and a 1 year high of $3.25. The company has a debt-to-equity ratio of 0.11, a quick ratio of 2.47 and a current ratio of 2.47. The company has a market capitalization of $37.43 million, a P/E ratio of -0.73 and a beta of 1.96. The company’s fifty day moving average is $0.91 and its two-hundred day moving average is $1.53.

Cue Biopharma (NASDAQ:CUE) last released its earnings results on Wednesday, August 14th. The company reported ($0.20) EPS for the quarter, topping the consensus estimate of ($0.29) by $0.09. Cue Biopharma had a negative net margin of 711.84% and a negative return on equity of 128.30%. The company had revenue of $2.66 million during the quarter, compared to analysts’ expectations of $1.12 million. During the same quarter last year, the business earned ($0.29) EPS. Analysts forecast that Cue Biopharma will post -0.93 earnings per share for the current year.

Institutional Trading of Cue Biopharma

Several hedge funds and other institutional investors have recently made changes to their positions in CUE. Vanguard Group Inc. lifted its stake in shares of Cue Biopharma by 7.1% in the first quarter. Vanguard Group Inc. now owns 2,283,362 shares of the company’s stock valued at $4,316,000 after purchasing an additional 150,457 shares during the period. Point72 Asia Singapore Pte. Ltd. acquired a new position in Cue Biopharma during the second quarter worth about $66,000. Wedmont Private Capital raised its position in Cue Biopharma by 100.0% during the first quarter. Wedmont Private Capital now owns 40,000 shares of the company’s stock worth $76,000 after acquiring an additional 20,000 shares during the last quarter. Finally, Legacy Capital Group California Inc. acquired a new position in Cue Biopharma during the fourth quarter worth about $26,000. Institutional investors and hedge funds own 35.04% of the company’s stock.

Cue Biopharma Company Profile

Cue Biopharma, Inc, a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells directly within the patient's body. Its lead drug product candidate is CUE-101 for the treatment of human papilloma virus (HPV16+)-driven recurrent/metastatic head and neck cancer.